Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SODIUM BICARBONATE CLAIMS FOR OVERINDULGENCE WILL BE DISALLOWED BY FDA

This article was originally published in The Tan Sheet

Executive Summary

SODIUM BICARBONATE CLAIMS FOR OVERINDULGENCE WILL BE DISALLOWED BY FDA in response to reports of rare, but potentially fatal, gastric ruptures. Under separate proposed amendments to the antacid final monograph and the internal analgesic tentative final monograph published in the Feb. 2 Federal Register, companies selling OTC products containing sodium bicarbonate or the combination of an analgesic and sodium bicarbonate would no longer be allowed to use the claims: "for the relief of over indulgence in food and drink" and "for relief of hangover."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel